Default: Lung Cancer

ISSN: 0169-5002

Journal Home

Journal Guideline

Lung Cancer Q1 Unclaimed

Elsevier Ireland Ltd Ireland
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Lung Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 141. It has an SJR impact factor of 1,609 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,609.

Lung Cancer focuses its scope in these topics and keywords: lung, cancer, cell, nonsmall, combination, chemotherapy, egfr, treatment, patients, chm, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Lung Cancer

1,609

SJR Impact factor

141

H Index

221

Total Docs (Last Year)

993

Total Docs (3 years)

8398

Total Refs

4862

Total Cites (3 years)

876

Citable Docs (3 years)

4.44

Cites/Doc (2 years)

38

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


lung, cancer, cell, nonsmall, combination, chemotherapy, egfr, treatment, patients, chm, elevated, egfrtki, ct, count, appalachiaoral, adjuvant, advanced, clinical, cisplatin, americans, chinese, caucasiansincidence, carcinomadoes, carcinomadifferences, cancergenetic, african, baseline, attract, areas, algorithm,



Best articles by citations

248 High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): A new challenge

View more

Cooking oil fumes and risk of lung cancer in women in rural Gansu, China

View more

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma

View more

Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer

View more

A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer

View more

78 A phase II study of paclitaxel (Taxol®) and ifosfamide (Holoxan®) in advanced non-small cell lung cancer

View more

High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients

View more

Co-expression of epidermal growth factor receptor and transforming growth factor-a is independent of ras mutations in lung adenocarcinoma

View more

Criteria of functional and oncological operability in surgery for lung cancer: A multicenter study

View more

Reply to Grannis

View more

Why are bronchopulmonary carcinoid tumours unique?

View more

127 Spirometric control following vinca alkaloids in patients receiving mitomycin

View more
SHOW MORE ARTICLES

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial

View more

168 A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC)

View more

250 Phase III study of the value of adding cisplatin (C) and etoposide (E) to radiation in patients with locally advanced squamous cell carcinoma of the lung (SQCL). A multicentric swedish study of 302 patients

View more

Overview of lung cancer screening and early cancer detection

View more

Metastasis to the penis in a patient with squamous cell carcinoma of the lung with a review of reported cases

View more

A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC). Effective palliation and patients' convenience

View more

High-resolution computed tomography of bronchioloalveolar cell carcinoma

View more

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

View more

63 Navelbine (NVB), and fractionated doses of cisplatin (CDDP) - 20 mg/m2/5 days - in the management of advanced non-small cell lung cancer: An overview of 3 phase II trials

View more

Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas

View more

275 Anti-cachectic effect of clarithromycin in inoperable non-small cell lung cancer patients

View more

Diagnosis and Treatment of Lung Cancer. An Evidence-Based Guide for the Practicing Clinician

View more

FAQS